[Stage-adjusted treatment of idiopathic Parkinson syndrome].
The treatment of idiopathic Parkinson's disease has been divided in 3 different phases. In the first phase the patient's disability is still minimal and a treatment with selegiline (possibly combined with an anticholinergic drug) is sufficient. In the second phase the treatment with levodopa (plus an decarboxylase inhibitor) becomes indispensable. In order to minimize the problems of long-term therapy a dopaminergic agonist (mostly bromocriptine) is added. The third phase is characterized by these problems. Some measures are discussed which may help to increase the patients' quality of life.
Ludin
H P
HP
Klinik für Neurologie, Kantonsspitals St Gallen, Schweiz.
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D018680:Cholinergic Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D004185:Disability Evaluation; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000145:classification / Q000188:drug therapy*; D012642:Selegiline / Q000009:adverse effects / Q000627:therapeutic use
D000978:Antiparkinson Agents; D018680:Cholinergic Antagonists; D012642:Selegiline; D001971:Bromocriptine; D007980:Levodopa; D002262:Carboxy-Lyases
Die stadiengerechte Behandlung des idiopathischen Parkinson-Syndroms.